litlas
Log inCreate account

Mark G. Currie

Active 1983–2024

80
Papers
18,215
Citations
69
h-index
79
i10-index

Citations

Citations per year for Mark G. Currie1972: 1 citations1983: 9 citations1984: 82 citations1985: 138 citations1986: 121 citations1987: 52 citations1988: 49 citations1989: 33 citations1990: 15 citations1991: 13 citations1992: 19 citations1993: 31 citations1994: 65 citations1995: 113 citations1996: 146 citations1997: 166 citations1998: 210 citations1999: 167 citations2000: 189 citations2001: 188 citations2002: 185 citations2003: 154 citations2004: 159 citations2005: 113 citations2006: 118 citations2007: 105 citations2008: 84 citations2009: 82 citations2010: 98 citations2011: 99 citations2012: 115 citations2013: 85 citations2014: 56 citations2015: 66 citations2016: 96 citations2017: 74 citations2018: 89 citations2019: 201 citations2020: 228 citations2021: 236 citations2022: 147 citations2023: 99 citations2024: 168 citations2025: 64 citations2026: 2 citations1973–1982: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,466 citing papers, 35.3% of this breakdownUnited Kingdom: 340 citing papers, 8.2% of this breakdownChina: 251 citing papers, 6.1% of this breakdownJapan: 210 citing papers, 5.1% of this breakdownGermany: 205 citing papers, 4.9% of this breakdownItaly: 197 citing papers, 4.8% of this breakdownCanada: 167 citing papers, 4% of this breakdownAustralia: 109 citing papers, 2.6% of this breakdownFrance: 108 citing papers, 2.6% of this breakdownIndia: 90 citing papers, 2.2% of this breakdownNetherlands: 81 citing papers, 2% of this breakdownSpain: 80 citing papers, 1.9% of this breakdown
0%35.3%Other 20.3%

Institutions

Fields

  • Medicine64.8%
  • Biochemistry, Genetics and Molecular Biology17.3%
  • Neuroscience4.2%
  • Immunology and Microbiology3.7%
  • Agricultural and Biological Sciences2%
  • Chemistry1.9%
  • Other6.1%

Topics

  • Nitric Oxide and Endothelin Effects7.9%
  • Gastrointestinal motility and disorders3.6%
  • Inflammatory mediators and NSAID effects3%
  • Eicosanoids and Hypertension Pharmacology2.6%
  • Osteoarthritis Treatment and Mechanisms2.4%
  • Heart Failure Treatment and Management2.1%
  • Other78.4%

Coauthors

All papers

Open in search
  1. Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

    Authors: William D. Chey, Anthony Lembo, Bernard J. Lavins, Steven J. Shiff, Caroline B. Kurtz, Mark G. Currie, James E. MacDougall, Xinwei D. Jia, James Shao, Donald A. Fitch, Mollie Baird, Harvey Schneier, Jeffrey M. Johnston - The American Journal of Gastroenterology 2012 cited by 451

  2. Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3′,5′-Monophosphate

    Authors: Joel Castro, Andrea M. Harrington, Patrick A. Hughes, Christopher M. Martin, Pei Ge, Courtney Shea, Hong Jin, Sarah Jacobson, Gerhard Hannig, Elizabeth A. Mann, Mitchell B. Cohen, James E. MacDougall, Bernard J. Lavins, Caroline B. Kurtz, Inmaculada Silos‐Santiago, Jeffrey M. Johnston, Mark G. Currie, L. Ashley Blackshaw, Stuart M. Brierley - Gastroenterology 2013 cited by 294

  3. Two Randomized Trials of Linaclotide for Chronic Constipation

    Authors: Anthony Lembo, Harvey Schneier, Steven J. Shiff, Caroline B. Kurtz, James E. MacDougall, Xinwei D. Jia, James Shao, Bernard J. Lavins, Mark G. Currie, Donald A. Fitch, Brenda I. Jeglinski, Paul Eng, Susan M. Fox, Jeffrey M. Johnston - New England Journal of Medicine 2011 cited by 372

  4. A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

    Authors: Satish S.C. Rao, Anthony Lembo, Steven J. Shiff, Bernard J. Lavins, Mark G. Currie, Xinwei D. Jia, Kelvin Shi, James E. MacDougall, James Shao, Paul Eng, Susan M. Fox, Harvey Schneier, Caroline B. Kurtz, Jeffrey M. Johnston - The American Journal of Gastroenterology 2012 cited by 377

  5. Cyclooxygenase 2‐dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants

    Authors: Medora M. Hardy, Karen Seibert, Pamela T. Manning, Mark G. Currie, B. Mark Woerner, Dorothy Edwards, Alane Koki, Catherine S. Tripp - Arthritis & Rheumatism 2002 cited by 303

  6. Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

    Authors: Robert Busby, Marco M. Kessler, Wilmin Bartolini, Alexander P. Bryant, Gerhard Hannig, Carolyn S. Higgins, Robert Solinga, Jenny Tobin, James Wakefield, Caroline B. Kurtz, Mark G. Currie - Journal of Pharmacology and Experimental Therapeutics 2012 cited by 136

  7. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

    Authors: Philip Schoenfeld, Brian E. Lacy, William D. Chey, Anthony Lembo, Caroline B. Kurtz, David S. Reasner, Wieslaw Bochenek, Kenneth Tripp, Mark G. Currie, Susan M. Fox, Rick E. Blakesley, Christopher R. O'Dea, Nicholas Omniewski, Michael L. Hall - The American Journal of Gastroenterology 2017 cited by 75

  8. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

    Authors: John P. Hanrahan, Jelena Seferović, James Wakefield, Phebe Wilson, Jennifer Chickering, Joon Jung, Kenneth E. Carlson, Daniel P. Zimmer, Andrew L. Frelinger, Alan D. Michelson, Linda Morrow, Michael Hall, Mark G. Currie, G. Todd Milne, Albert T. Profy - Diabetologia 2019 cited by 33

  9. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

    Authors: Robert Busby, Alexander P. Bryant, Wilmin Bartolini, Etchell A. Cordero, Gerhard Hannig, Marco M. Kessler, Shalina Mahajan‐Miklos, Christine M. Pierce, Robert Solinga, Li Jing Sun, Jenny Tobin, Caroline B. Kurtz, Mark G. Currie - European Journal of Pharmacology 2010 cited by 248

  10. Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation

    Authors: Jeffrey M. Johnston, Caroline B. Kurtz, James E. MacDougall, Bernard J. Lavins, Mark G. Currie, Donald A. Fitch, Chris OʼDea, Mollie Baird, Anthony Lembo - Gastroenterology 2010 cited by 230

  11. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions

    Authors: Yunsheng Yang, Yunsheng Yang, Jing‐Yuan Fang, Xiaozhong Guo, Ning Dai, Xizhong Shen, Youlin Yang, Youlin Yang, Jing Sun, Bal Raj Bhandari, David S. Reasner, Jacquelyn A. Cronin, Mark G. Currie, Jeffrey M. Johnston, Peter YF. Zeng, N Montreewasuwat, George Zhijian Chen, Sam Lim - Journal of Gastroenterology and Hepatology 2018 cited by 80

  12. A Fluorometric Assay for the Measurement of Nitrite in Biological Samples

    Authors: Thomas P. Misko, Roger Schilling, Daniela Salvemini, W. Michael Moore, Mark G. Currie - Analytical Biochemistry 1993 cited by 1,023

  13. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract

    Authors: Alexander P. Bryant, Robert Busby, Wilmin Bartolini, Etchell A. Cordero, Gerhard Hannig, Marco M. Kessler, Christine M. Pierce, Robert Solinga, Jenny Tobin, Shalina Mahajan‐Miklos, Mitchell B. Cohen, Caroline B. Kurtz, Mark G. Currie - Life Sciences 2010 cited by 224

  14. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics

    Authors: Trevor T. Hansel, Sergei A. Kharitonov, Louise Donnelly, Edward M. Erin, Mark G. Currie, William M. Moore, Pamela T. Manning, David P. Recker, Peter J. Barnes - The FASEB Journal 2003 cited by 208

  15. Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells

    Authors: Guang Liu, Courtney Shea, Juli E. Jones, Gavrielle M. Price, William Warren, Elisabeth Lonie, Shu Yan, Mark G. Currie, Albert T. Profy, Jaime L. Masferrer, Daniel P. Zimmer - American Journal of Physiology-Renal Physiology 2020 cited by 29

  16. Nitric oxide activates cyclooxygenase enzymes.

    Authors: Daniela Salvemini, Thomas P. Misko, Jaime L. Masferrer, Karen Seibert, Mark G. Currie, Philip Needleman - National Academy of Sciences, Proceedings of the National Academy of Sciences 1993 cited by 1,404

  17. Nitric oxide: a key mediator in the early and late phase of carrageenan‐induced rat paw inflammation

    Authors: Daniela Salvemini, Zhiqiang Wang, Pamela S. Wyatt, David Bourdon, Margaret H. Marino, Pamela T. Manning, Mark G. Currie - British Journal of Pharmacology 1996 cited by 670

  18. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase

    Authors: Jean‐Pierre Pelletier, Dragan Jovanović, Julio Fernandes, Pamela T. Manning, Jane R. Connor, Mark G. Currie, John A. Di Battista, Johanne Martel‐Pelletier - Arthritis & Rheumatism 1998 cited by 344

  19. Efficacy of Linaclotide for Patients With Chronic Constipation

    Authors: Anthony Lembo, Caroline B. Kurtz, James E. MacDougall, Bernard J. Lavins, Mark G. Currie, Donald A. Fitch, Brenda I. Jeglinski, Jeffrey M. Johnston - Gastroenterology 2010 cited by 235

  20. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial

    Authors: Brian E. Lacy, Ron Schey, Steven J. Shiff, Bernard J. Lavins, Susan M. Fox, Xinwei D. Jia, Rick E. Blakesley, Xinming Hao, Jacquelyn A. Cronin, Mark G. Currie, Caroline B. Kurtz, Jeffrey M. Johnston, Anthony Lembo - PLoS ONE 2015 cited by 81

  21. sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH

    Authors: Katherine C. Hall, Sylvie G. Bernier, Sarah Jacobson, Guang Liu, Ping Y. Zhang, Renee Sarno, Victoria Catanzano, Mark G. Currie, Jaime L. Masferrer - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 57

  22. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease

    Authors: John P. Hanrahan, Ian H. de Boer, George L. Bakris, Phebe Wilson, James Wakefield, Jelena P. Seferović, Jennifer Chickering, Yueh‐tyng Chien, Kenneth E. Carlson, Michael D. Cressman, Mark G. Currie, G. Todd Milne, Albert T. Profy - Clinical Journal of the American Society of Nephrology 2020 cited by 40

  23. The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases

    Authors: Susana S. Correia, Rajesh R. Iyengar, Peter Germano, Kim San Tang, Sylvie G. Bernier, Chad D. Schwartzkopf, Jenny Tobin, Thomas Lee, Guang Liu, Sarah Jacobson, Andrew Carvalho, Glen R. Rennie, Joon Jung, Paul A. Renhowe, Elisabeth Lonie, Christopher J. Winrow, John R. Hadcock, Juli E. Jones, Mark G. Currie - Frontiers in Pharmacology 2021 cited by 36

  24. A Nonpeptidyl Mimic of Superoxide Dismutase with Therapeutic Activity in Rats

    Authors: Daniela Salvemini, Zhiqiang Wang, Jay L. Zweíer, Alexandre Samouilov, Heather Macarthur, Thomas P. Misko, Mark G. Currie, Salvatore Cuzzocrea, James A. Sikorski, Dennis P. Riley - Science 1999 cited by 499